Literature DB >> 21795759

Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica.

Nemu Matsuya1, Mika Komori, Kyouichi Nomura, Shunya Nakane, Takayasu Fukudome, Hirofumi Goto, Hirokazu Shiraishi, Klaus-Peter Wandinger, Hidenori Matsuo, Takayuki Kondo.   

Abstract

In neuromyelitis optica (NMO), B-cell autoimmunity to aquaporin-4 (AQP4) has been shown to be essential. However, the role of T cells remains ambiguous. Here, we first showed an increase in CD69+ activated T cells in PBMCs during NMO relapses. Next, T-cell responses to AQP4 and myelin peptides were studied in 12 NM0 patients, 10 multiple sclerosis (MS) patients and 10 healthy subjects (HS). Four hours after adding 1 of 28 overlapping AQP4 peptides, a mixture of AQP4 peptides (AQP4-M) or one of six distinct myelin peptides to 2-day cultured PBMC, CD69 expression on CD4+ T cells was examined. Data were analyzed by paired t-test, frequency of samples with 3-fold increase of CD69 on CD4+ cells (fSI3) and mean stimulation index (mSI). The T-cell response to AQP4-M was significantly increased in NMO (fSI3 = 10/12, mSI = 5.50), with AQP4 (11-30) and AQP4 (91-110) representing the two major epitopes (AQP4 (11-30), fSI3 = 11/12, mSI = 16.0 and AQP4 (91-110), fSI3 = 11/12, mSI = 13.0). Significant but less extensive responses to these two epitopes were also observed in MS and HS. Significant reactivities against AQP4 (21-40), AQP4 (61-80), AQP4 (101-120), AQP4 (171-190) and AQP4 (211-230) were exclusively found in NMO. In addition, responses to AQP4 (81-100) were higher and more frequently detected in NMO, without reaching statistical significance. Interestingly, among the six myelin peptides studied, proteolipid protein (95-116) induced a significant T-cell response in NMO (fSI3 = 7/12, mSI = 4.60). Our study suggests that cellular as well as humoral responses to AQP4 are necessary for NMO development and that the immune response to myelin protein may contribute to disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21795759     DOI: 10.1093/intimm/dxr056

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  30 in total

Review 1.  The adaptive immune system in diseases of the central nervous system.

Authors:  David C Wraith; Lindsay B Nicholson
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 2.  Experimental models of neuromyelitis optica: current status, challenges and future directions.

Authors:  Minshu Li; Yaping Yan
Journal:  Neurosci Bull       Date:  2015-06-24       Impact factor: 5.203

3.  Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica.

Authors:  Takashi Kageyama; Mika Komori; Katsuichi Miyamoto; Akihiko Ozaki; Toshihiko Suenaga; Ryosuke Takahashi; Susumu Kusunoki; Sadayuki Matsumoto; Takayuki Kondo
Journal:  J Neurol       Date:  2012-10-18       Impact factor: 4.849

4.  Cross-immunoreactivity between bacterial aquaporin-Z and human aquaporin-4: potential relevance to neuromyelitis optica.

Authors:  Zhihua Ren; Yan Wang; Tao Duan; Jilpa Patel; Thomas Liggett; Eileah Loda; Sarang Brahma; Rajendra Goswami; Carrie Grouse; Richard Byrne; Dusan Stefoski; Adil Javed; Stephen D Miller; Roumen Balabanov
Journal:  J Immunol       Date:  2012-09-24       Impact factor: 5.422

5.  Helicobacter pylori and gut microbiota in multiple sclerosis versus Alzheimer's disease: 10 pitfalls of microbiome studies.

Authors:  Ah-Mee Park; Seiichi Omura; Mitsugu Fujita; Fumitaka Sato; Ikuo Tsunoda
Journal:  Clin Exp Neuroimmunol       Date:  2017-07-23

Review 6.  The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica.

Authors:  Claudia F Lucchinetti; Yong Guo; Bogdan F Gh Popescu; Kazuo Fujihara; Yasuto Itoyama; Tatsuro Misu
Journal:  Brain Pathol       Date:  2014-01       Impact factor: 6.508

Review 7.  [Neuromyelitis optica].

Authors:  B Wildemann; S Jarius; F Paul
Journal:  Nervenarzt       Date:  2013-04       Impact factor: 1.214

8.  The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients.

Authors:  Ulisses C Linhares; Patrícia B Schiavoni; Priscila O Barros; Taissa M Kasahara; Bruna Teixeira; Thais B Ferreira; Regina Alvarenga; Joana Hygino; Morgana M M Vieira; Vera Carolina B Bittencourt; Regis M Andrade; Arnaldo F Andrade; Cleonice A M Bento
Journal:  J Clin Immunol       Date:  2012-09-05       Impact factor: 8.317

Review 9.  Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

Authors:  S Jarius; B Wildemann; F Paul
Journal:  Clin Exp Immunol       Date:  2014-05       Impact factor: 4.330

Review 10.  Is CD69 an effective brake to control inflammatory diseases?

Authors:  Roberto González-Amaro; José R Cortés; Francisco Sánchez-Madrid; Pilar Martín
Journal:  Trends Mol Med       Date:  2013-08-13       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.